Objective: Although cerebral microbleeds predict the occurrence and recurrence of cerebrovascular events in stroke patients, their clinical impacts are unclear in coronary artery disease patients. We aimed to investigate the clinical effect of the presence of cerebral microbleeds in patients with coronary artery disease receiving antithrombotic treatment.
Methods: We included 447 coronary artery disease patients taking at least one thrombotic agent who underwent brain MRI. The association between the presence of cerebral microbleeds and incidence of major adverse cardiac and cerebrovascular events was investigated.
Results: Cerebral microbleeds were identified in 18.7% of patients. Median follow-up duration was 1055 (interquartile range, 781-1172) days. Kaplan-Meier survival analysis demonstrated that patients with cerebral microbleeds had a higher incidence of major adverse cardiac and cerebrovascular events than those without (log-rank P = 0.003). A multivariate Cox regression analysis revealed that the presence of cerebral microbleeds was independently correlated with the occurrence of major adverse cardiac and cerebrovascular events after adjusting for other classical risk factors of coronary artery disease (hazard ratio 1.965, 95% confidence interval 1.086-3.556, P = 0.026). Hypertension was associated with the presence of cerebral microbleeds. The cut-off values to maximize the predictive power of SBP and DBP were 132 and 74 mmHg, respectively (P < 0.001).
Conclusion: The presence of cerebral microbleeds predicts major adverse cardiac and cerebrovascular events in coronary artery disease patients receiving antithrombotic treatment. Evaluation of cerebral microbleeds and hypertension treatment complying with the established guidelines may be beneficial in the management of coronary artery disease patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/HJH.0000000000002615 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms.
Nat Rev Neurol
January 2025
J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Three monoclonal antibodies directed against specific forms of the amyloid-β (Aβ) peptide have been granted accelerated or traditional approval by the FDA as treatments for Alzheimer disease, representing the first step towards bringing disease-modifying treatments for this disease into clinical practice. Here, we review the detection, underlying pathophysiological mechanisms and clinical implications of amyloid-related imaging abnormalities (ARIA), the most impactful adverse effect of anti-Aβ immunotherapy. ARIA appears as regions of oedema or effusions (ARIA-E) in brain parenchyma or sulci or as haemorrhagic lesions (ARIA-H) in the form of cerebral microbleeds, convexity subarachnoid haemorrhage, cortical superficial siderosis or intracerebral haemorrhage.
View Article and Find Full Text PDFAssociation of small vessel disease progression with longitudinal cognitive decline across mild cognitive impairment.
J Alzheimers Dis
January 2025
Department of Radiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Background: Cerebral small vessel disease (SVD) is the leading cause of vascular dementia. However, it is unclear whether the individual SVD or global SVD progression correlates with cognitive decline across mild cognitive impairment (MCI) subjects.
Objective: To investigate the association of small vessel disease progression with longitudinal cognitive decline across MCI.
Circadian rest-activity rhythm pattern in the elderly with cerebral small vessel disease: Using multiple estimated methods.
J Alzheimers Dis
January 2025
Department of Neurology, The Seventh Medical Center of PLA General Hospital, Beijing, China.
Disruption of circadian rest-activity rhythm (RAR) has been found in many neurological disorders. In this study, actigraphic data were collected and analyzed to identify the RAR pattern in the elderly with cerebral small vessel disease. 115 cerebral small vessel disease (CSVD) cases were recruited.
View Article and Find Full Text PDFValidation of a Deep Learning-Based Method for Accelerating Susceptibility-Weighted Imaging in Clinical Settings.
NMR Biomed
February 2025
Department of Radiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Susceptibility-weighted imaging (SWI) has been widely used in clinical contexts, in which the speed of acquisition is frequently a critical issue. In this study, we aim to test the feasibility of a deep learning (DL)-based reconstruction method for accelerating SWI acquisition in clinical settings. A total of 61 subjects were consecutively enrolled.
View Article and Find Full Text PDFTwo-dimensional T2*-weighted multi-shot echo-planar imaging to detect cerebral microbleeds in neurocognitive disorders: A time-efficient alternative to susceptibility weighted angiography.
Eur J Radiol
January 2025
Department of Radiology, Rouen University Hospital, Rouen, Normandy, France. Electronic address:
Purpose: To evaluate the effectiveness of ultra-fast two-dimensional (2D) T2*-weighted multi-shot echo-planar imaging (MS-EPI) for the detection of cerebral microbleeds (CMB) in cognitive disorders.
Methods: Sixty-eight patients referred for neuroimaging to investigate cognitive disorders underwent 3 T MR imaging, with both 2D T2*-weighted MS-EPI and susceptibility-weighted angiography (SWAN). Microbleeds were separately assessed on 2D T2*-weighted MS-EPI and SWAN by 2 raters.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!